Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2140)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 26.04.24 23:20:55 von
neuester Beitrag 26.04.24 23:20:55 von
Beiträge: 22.815
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 80
Gesamt: 1.231.795
Gesamt: 1.231.795
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVAX
3,8085
EUR
+3,58 %
+0,1315 EUR
Letzter Kurs 26.04.24 Tradegate
Neuigkeiten
20.04.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 7,3500 | +43,84 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
AGC Biologics Expands Partnership with Novavax
by Diane Hunt on 8/10/20 1:05 PM
http://www.agcbio.com/resource-center/news/agc-biologics-exp…
Manufacturing of Novavax’ Matrix-M™ Adjuvant for Novel COVID-19 Vaccine Expands to Seattle
(SEATTLE), August 10, 2020 -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases. AGC Biologics is currently preparing to manufacture Matrix-M™, the adjuvant component of Novavax’ coronavirus vaccine, NVX-CoV2373, from its facility in Copenhagen. AGC Biologics will now expand supply of Matrix-M adjuvant for the vaccine from its facility in Seattle to ensure supply for the United States.
...
by Diane Hunt on 8/10/20 1:05 PM
http://www.agcbio.com/resource-center/news/agc-biologics-exp…
Manufacturing of Novavax’ Matrix-M™ Adjuvant for Novel COVID-19 Vaccine Expands to Seattle
(SEATTLE), August 10, 2020 -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases. AGC Biologics is currently preparing to manufacture Matrix-M™, the adjuvant component of Novavax’ coronavirus vaccine, NVX-CoV2373, from its facility in Copenhagen. AGC Biologics will now expand supply of Matrix-M adjuvant for the vaccine from its facility in Seattle to ensure supply for the United States.
...
Novavax Reports Second Quarter 2020 Financial and Operational Results
Aug 10, 2020 at 4:02 PM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
Novavax reported a net loss of $17.5 million, or $0.30 per share, for the second quarter of 2020, compared to a net loss of $39.6 million, or $1.69 per share, for the second quarter of 2019. For the six months ended June 30, 2020, the net loss was $43.4 million, or $0.84 per share, compared to a net loss of $82.8 million, or $3.77 per share, for the same period in 2019.
Novavax revenue in the second quarter of 2020 was $35.5 million, compared to $3.4 million in the same period in 2019. This significant increase was due to increased development activities relating to NVX-CoV2373 under the CEPI agreement.
Research and development expenses increased 15% to $34.8 million in the second quarter of 2020, compared to $30.4 million in the same period in 2019. The increase was primarily due to increased development activities relating to NVX-CoV2373 under the CEPI agreement, partially offset by decreased employee-related and other costs and development activities of ResVax as compared to the same period in 2019.
General and administrative expenses increased 84% to $17.7 million in the second quarter of 2020, compared to $9.6 million for the same period in 2019. This increase was primarily due to increased professional fees relating to the Novavax CZ acquisition and supporting our NVX-CoV2373 program and increased employee-related expenses.
As of June 30, 2020, Novavax had $609.5 million in cash, cash equivalents, marketable securities and restricted cash, compared to $82.2 million as of December 31, 2019. Net cash provided by operating activities for the first six months of 2020 was $92.5 million, compared to net cash used in operating activities was $80.6 million for same period in 2019.
sieht doch ganz gut aus
Aug 10, 2020 at 4:02 PM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
Novavax reported a net loss of $17.5 million, or $0.30 per share, for the second quarter of 2020, compared to a net loss of $39.6 million, or $1.69 per share, for the second quarter of 2019. For the six months ended June 30, 2020, the net loss was $43.4 million, or $0.84 per share, compared to a net loss of $82.8 million, or $3.77 per share, for the same period in 2019.
Novavax revenue in the second quarter of 2020 was $35.5 million, compared to $3.4 million in the same period in 2019. This significant increase was due to increased development activities relating to NVX-CoV2373 under the CEPI agreement.
Research and development expenses increased 15% to $34.8 million in the second quarter of 2020, compared to $30.4 million in the same period in 2019. The increase was primarily due to increased development activities relating to NVX-CoV2373 under the CEPI agreement, partially offset by decreased employee-related and other costs and development activities of ResVax as compared to the same period in 2019.
General and administrative expenses increased 84% to $17.7 million in the second quarter of 2020, compared to $9.6 million for the same period in 2019. This increase was primarily due to increased professional fees relating to the Novavax CZ acquisition and supporting our NVX-CoV2373 program and increased employee-related expenses.
As of June 30, 2020, Novavax had $609.5 million in cash, cash equivalents, marketable securities and restricted cash, compared to $82.2 million as of December 31, 2019. Net cash provided by operating activities for the first six months of 2020 was $92.5 million, compared to net cash used in operating activities was $80.6 million for same period in 2019.
sieht doch ganz gut aus
Novavax Inks Vaccine Deals In Japan, India; Analyst Sees 70% Stock Upside
https://finance.yahoo.com/news/novavax-inks-vaccine-deals-ja…
https://finance.yahoo.com/news/novavax-inks-vaccine-deals-ja…
Antwort auf Beitrag Nr.: 64.681.753 von DasTier666 am 07.08.20 12:13:08Danke für die Infos!
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Aug 07, 2020 at 5:26 AM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
GAITHERSBURG, Md. and OSAKA, Japan, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.
“Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX‑CoV2373,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We look forward to collaborating with Takeda to rapidly develop, produce and commercialize the vaccine in Japan.”
Novavax and Takeda are partnering on manufacturing, clinical development and regulatory activities in Japan. Novavax will license and transfer manufacturing technologies to enable Takeda to manufacture the vaccine antigen and will supply the Matrix-M adjuvant to Takeda. Takeda will be responsible for regulatory submission to the MHLW and will produce and distribute NVX‑CoV2373 in Japan.
“Nothing is more important right now than protecting the world against COVID-19. We are excited to collaborate with Novavax to bring their promising vaccine candidate to Japan,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “Today’s announcement builds upon our ongoing support of pandemic preparedness and demonstrates Takeda’s commitment to the health and well-being of the Japanese population.”
Novavax will be entitled to receive payments based on the achievement of certain development and commercial milestones, as well as a portion of proceeds from the vaccine.
Aug 07, 2020 at 5:26 AM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
GAITHERSBURG, Md. and OSAKA, Japan, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.
“Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX‑CoV2373,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We look forward to collaborating with Takeda to rapidly develop, produce and commercialize the vaccine in Japan.”
Novavax and Takeda are partnering on manufacturing, clinical development and regulatory activities in Japan. Novavax will license and transfer manufacturing technologies to enable Takeda to manufacture the vaccine antigen and will supply the Matrix-M adjuvant to Takeda. Takeda will be responsible for regulatory submission to the MHLW and will produce and distribute NVX‑CoV2373 in Japan.
“Nothing is more important right now than protecting the world against COVID-19. We are excited to collaborate with Novavax to bring their promising vaccine candidate to Japan,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “Today’s announcement builds upon our ongoing support of pandemic preparedness and demonstrates Takeda’s commitment to the health and well-being of the Japanese population.”
Novavax will be entitled to receive payments based on the achievement of certain development and commercial milestones, as well as a portion of proceeds from the vaccine.
Trading Spotlight
Antwort auf Beitrag Nr.: 64.670.341 von Magnetfeldfredy am 06.08.20 16:21:35Ich bin hier auch schon mehrere Jahre dabei und habe die RSV Desaster miterlebt. Meinen Einsatz habe ich bereits vor einiger Zeit gesichert und jetzt liegen noch 80 Stücke zu 24€ im Depot (Splitt bereinigt), als Schmerzensgeld 
.
Das Unternehmen muss zeigen, dass es einen Impfstoff durch alle Phasen bringen und ihn auch vermarkten kann. So lange bleiben die Stücke im Depot. Meine Hoffnung liegt hier bei NanoFlu und hoffentlich kann auch der RSV Impfstoff vertrieben werden. Den Covid19 Impfstoff sehe ich immer noch als Zugabe, spannender finde ich da den Malaria Impfstoff. Am Montag gibts die nächsten Zahlen und eventuell einen Ausblick auf Kommendes.
Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020
Aug 06, 2020 at 6:45 AM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
Novavax and Serum Institute of India Announce Development and Commercial Collaboration
Aug 06, 2020 at 4:49 PM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
.Das Unternehmen muss zeigen, dass es einen Impfstoff durch alle Phasen bringen und ihn auch vermarkten kann. So lange bleiben die Stücke im Depot. Meine Hoffnung liegt hier bei NanoFlu und hoffentlich kann auch der RSV Impfstoff vertrieben werden. Den Covid19 Impfstoff sehe ich immer noch als Zugabe, spannender finde ich da den Malaria Impfstoff. Am Montag gibts die nächsten Zahlen und eventuell einen Ausblick auf Kommendes.
Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020
Aug 06, 2020 at 6:45 AM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
Novavax and Serum Institute of India Announce Development and Commercial Collaboration
Aug 06, 2020 at 4:49 PM EDT
https://ir.novavax.com/news-releases/news-release-details/no…
Ja, ich war bei 4,5 US Dollar drin, aber auch vor 2 Jahren vor dem reverse Split, 1:20, dh. Novavax ist jetzt bei 8-9 US Dollar für mich, trotzdem habe ich satte Gewinne gemacht, war aber nicht immer dabei, jetzt wieder:
Novavax price target raised to $290
from $132 at H.C. Wainwright 06:38 NVAX H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Novavax to $290 from $132 and keeps a Buy rating on the shares. The stock closed Wednesday up $16.32 to $173.49. NVX-CoV2373's "strong" Phase 1 results make the potential COVID-19 vaccine "hard to ignore," Bernardino tells investors in a research note. The analyst believes NVX-CoV2373 "demonstrated very competitive efficacy." If NVX-CoV2373's safety and efficacy in Phase 1 testing continue to be demonstrated in Phase 2 and 3, the vaccine could emerge as a leading option against the spread of SARSCoV- 2 and should see broad adoption, "which would be highly lucrative for Novavax," says Bernardino. The analyst looks for the company to become a "major player" in vaccine development in the near future and reiterates his "Top Pick" view on the shares.
Read more at:
https://thefly.com/landingPageNews.php?id=3140868
Novavax price target raised to $290
from $132 at H.C. Wainwright 06:38 NVAX H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Novavax to $290 from $132 and keeps a Buy rating on the shares. The stock closed Wednesday up $16.32 to $173.49. NVX-CoV2373's "strong" Phase 1 results make the potential COVID-19 vaccine "hard to ignore," Bernardino tells investors in a research note. The analyst believes NVX-CoV2373 "demonstrated very competitive efficacy." If NVX-CoV2373's safety and efficacy in Phase 1 testing continue to be demonstrated in Phase 2 and 3, the vaccine could emerge as a leading option against the spread of SARSCoV- 2 and should see broad adoption, "which would be highly lucrative for Novavax," says Bernardino. The analyst looks for the company to become a "major player" in vaccine development in the near future and reiterates his "Top Pick" view on the shares.Read more at:
https://thefly.com/landingPageNews.php?id=3140868
Antwort auf Beitrag Nr.: 64.655.668 von Magnetfeldfredy am 05.08.20 16:02:02Du warst dabei mit 4.5 usd ?
Wahnsinn, bin leider bei USD 150 raus, na ja von 4,5 auf 150 hat Mann auch nicht alle Tage....
Charles Duncan, Analyst von Cantor Fitzgerald, stuft die Novavax-Aktie (ISIN: US6700024010, WKN: A2PKMZ, Ticker-Symbol: NVV1, Nasdaq-Symbol: NVAX) weiterhin mit dem Votum "overweight" ein. Das Kursziel werde von 148 auf 211 USD erhöht. (Update vom 05.08.2020)
http://www.aktiencheck.de/exklusiv/Artikel-Novavax_Kursziela…
Eric Joseph, Analyst von J.P. Morgan Securities, stuft die Novavax-Aktie (ISIN: US6700024010, WKN: A2PKMZ, Ticker-Symbol: NVV1, Nasdaq-Symbol: NVAX) von "neutral" auf "overweight" hoch. Das Kursziel werde von 105 auf 275 USD angehoben. (Update vom 05.08.2020)
http://www.aktiencheck.de/exklusiv/category_analyst?analyst_…
http://www.aktiencheck.de/exklusiv/Artikel-Novavax_Kursziela…
Eric Joseph, Analyst von J.P. Morgan Securities, stuft die Novavax-Aktie (ISIN: US6700024010, WKN: A2PKMZ, Ticker-Symbol: NVV1, Nasdaq-Symbol: NVAX) von "neutral" auf "overweight" hoch. Das Kursziel werde von 105 auf 275 USD angehoben. (Update vom 05.08.2020)
http://www.aktiencheck.de/exklusiv/category_analyst?analyst_…
Durchsuchen
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |